Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis

A Multicenter, Open Label, 3-Month Safety Study with Tradipitant in Patients with Idiopathic or Diabetic Gastroparesis

This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.

Inclusion Criteria:

• Diagnosed with gastroparesis
• Demonstrated delayed gastric emptying
• Presence of moderate to severe nausea
• Body Mass Index (BMI) of ≥18 and ≤40 kg/m2

Exclusion Criteria:

• Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis
• A positive test for drugs of abuse at the screening or evaluation visits
• Pregnancy or nursing
• Evidence of uncontrolled blood glucose (including HbA1C >11% at screening or metabolic crisis in past 60 days)